Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06726161 · ClinicalTrials.gov registry record · Phase 1
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC
A Phase 1 study of HCC, sponsored by RayzeBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT06726161: Recruiting Phase 1 study of HCC, sponsored by RayzeBio.
NCT06726161 is a Phase 1 study of HCC that is actively recruiting participants, run by RayzeBio. The registered enrollment target is 70 participants, below the 196-participant average among 13 other HCC trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06726161, a Phase 1 study of HCC, is actively recruiting participants, sponsored by RayzeBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
A single arm, open-label Phase 1/1b study of the theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable HCC
Primary Outcome
To determine the RTA of RYZ801 in subjects with GPC3+ unresectable HCC (Dose Escalation only)
Conditions Studied
Interventions
- DIAGNOSTIC_TEST RYZ811
- DRUG RYZ801
Study Locations (2)
Alabama
- Research Facility - Birmingham
Michigan
- Research Facility - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-11-15 |
| Est. Completion | 2031-01 |
| Phase | Phase 1 |
What NCT06726161 shows while recruiting
NCT06726161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 196-participant average among 13 other HCC trials with a reported enrollment target (64% lower).
The record links to 1 condition, with HCC appearing as the primary indexed condition, and to 2 interventions - of which RYZ811 is the first listed.
NCT06726161 reports a single indexed study location in Alabama, Michigan.
Frequently Asked Questions
What is clinical trial NCT06726161 about?
NCT06726161 is a clinical study titled "Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC". A single arm, open-label Phase 1/1b study of the theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable HCC
What is the current status of trial NCT06726161?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2024-11-15. Estimated completion is 2031-01.
What conditions does trial NCT06726161 study?
This clinical trial studies the following conditions: HCC.
What interventions are being tested in trial NCT06726161?
The interventions under investigation include: RYZ811 (DIAGNOSTIC_TEST), RYZ801 (DRUG).
Who is sponsoring clinical trial NCT06726161?
This trial is sponsored by RayzeBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06726161 being conducted?
This trial has 2 study locations across Alabama, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HCC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06726161's enrollment target sits among peer trials
70 7th of 13 higher than 7 of 13 other HCC trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HCC trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC
ACTIVE NOT RECRUITING · Phase 1
-
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
COMPLETED · Phase 1
-
Multi-analyte Blood Test Clinical Trial
RECRUITING
-
HOPE Against Cancer Recurrence in HCC
RECRUITING · Phase 4
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
Y-90 Treatment Response Using Transarterial Radioembolization
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI